MicroRNA-223 is neuroprotective by targeting glutamate receptors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 46, 2012, Pages 18962-18967

  Harraz, Maged M ^a,b   Eacker, Stephen M ^a   Wang, Xueqing ^a   Dawson, Ted M ^a   Dawson, Valina L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR 2; MICRORNA 223; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG TARGETING; EXCITOTOXICITY; MALE; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3' UNTRANSLATED REGIONS; ANIMALS; CALCIUM; CALCIUM SIGNALING; EXCITATORY POSTSYNAPTIC POTENTIALS; HEK293 CELLS; HIPPOCAMPUS; HUMANS; MICE; MICRORNAS; N-METHYLASPARTATE; NEURODEGENERATIVE DISEASES; NEURONS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; STROKE;

EID: 84869205438     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1121288109     Document Type: Article

References (29)

1. Bartel DP (2009) MicroRNAs: Target recognition and regulatory functions. Cell 136(2):215-233.
2. Sayed D, Abdellatif M (2011) MicroRNAs in development and disease. Physiol Rev 91(3):827-887.
3. Farazi TA, Spitzer JI, Morozov P, Tuschl T (2011) miRNAs in human cancer. J Pathol 223(2):102-115.
4. Han M, Toli J, Abdellatif M (2011) MicroRNAs in the cardiovascular system. Curr Opin Cardiol 26(3):181-189.
5. Eacker SM, Dawson TM, Dawson VL (2009) Understanding microRNAs in neurodegeneration. Nat Rev Neurosci 10(12):837-841.
6. Gambari R, et al. (2011) Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development. Biochem Pharmacol 82(10):1416-1429.
7. Donnan GA, Fisher M, Macleod M, Davis SM (2008) Stroke. Lancet 371(9624):1612-1623.
8. Lee JM, Zipfel GJ, Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399(6738):Suppl):A7-A14.
9. Karr J, et al. (2009) Regulation of glutamate receptor subunit availability by micro-RNAs. J Cell Biol 185(4):685-697.
10. Saba R, et al. (2012) Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol Cell Biol 32(3):619-632.
11. Edbauer D, et al. (2010) Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 65(3):373-384.
12. Fazi F, et al. (2005) A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123(5):819-831.
13. Johnnidis JB, et al. (2008) Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451(7182):1125-1129.
14. Fazi F, et al. (2007) Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12(5):457-466.
15. Pulikkan JA, et al. (2010) Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 115(9):1768-1778.
16. Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303(5654):83-86.
17. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP (2003) Vertebrate microRNA genes. Science 299(5612):1540.
18. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15-20.
19. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22(22):4673-4680.
20. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10(10):1507-1517.
21. Kessler M, Baudry M, Lynch G (1989) Quinoxaline derivatives are high-affinity antagonists of the NMDA receptor-associated glycine sites. Brain Res 489(2):377-382.
22. Martel MA, et al. (2012) The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron 74(3):543-556.
23. Peng PL, et al. (2006) ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron 49(5):719-733.
24. Kwak S, Weiss JH (2006) Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. Curr Opin Neurobiol 16(3):281-287.
25. Liu SJ, Zukin RS (2007) Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci 30(3):126-134.
26. Sans N, et al. (2003) Aberrant formation of glutamate receptor complexes in hippocampal neurons of mice lacking the GluR2 AMPA receptor subunit. J Neurosci 23(28):9367-9373.
27. Sattler R, et al. (1999) Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284(5421):1845-1848.
28. Baek D, et al. (2008) The impact of microRNAs on protein output. Nature 455(7209):64-71.
29. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466(7308):835-840.